Featured Research

from universities, journals, and other organizations

Thwarting drug-resistant lung cancer with novel compound

Date:
April 8, 2014
Source:
City of Hope
Summary:
A novel compound, COH-SR4, can target and treat drug-resistant lung cancers, research suggests. The researchers conclude: "the results from our in-vitro and in-vivo studies reveal that COH-SR4 represents a novel candidate ... to target aggressive and drug-resistant lung cancers." They are working on further preclinical research in order to apply for human trials with the Food and Drug Administration, as well studying COH-SR4's ability to fight other cancers, diabetes and obesity.

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

Related Articles


However, a group of City of Hope researchers have identified and synthesized a novel compound -- called COH-SR4 -- that is effective against drug-resistant lung cancer. If its safety and efficacy pan out in future studies, COH-SR4 could play a vital role in treating lung cancers that no longer respond to first-line chemotherapy.

The COH-SR4 findings will be presented at the American Association for Cancer Research (AACR) annual meeting in San Diego on Monday, April 7.

"Based on the chemical structure of COH-SR4, we hypothesized that it caused cancer cell death by inhibiting the antioxidant activity of the mercapturic acid pathway," said Sanjay Awasthi, M.D., professor at City of Hope's Department of Medical Oncology & Therapeutics Research and senior author of the study.

In earlier studies, Awasthi and his colleagues found that nonsmall cell lung cancer and melanoma are responsive to the anti-cancer properties of COH-SR4, which was originally developed to suppress fat cell development and has also been found to improve glucose control and insulin sensitivity.

After observing the cancers' response, the researchers tested COH-SR4 on several types of lung cancer -- including types that are treatment-resistant -- in cell culture and animal models.

In the AACR presentation, Awasthi and his colleagues report that COH-SR4 did lead to lung cancer cell death without showing any toxicity in normal tissue.

Also, in a previously published paper in the journal Biochemical Pharmacology, Awasthi's team found that after two months of administering COH-SR4 orally to animal models, the average mass of lung cancer tumors in the treatment group were less than half of those in the control group (0.77 and 2.02 grams, respectively,) demonstrating that the drug inhibited tumor growth.

Additionally, they confirmed that COH-SR4 did work through inhibition of the mercapturic acid pathway, which then deactivated multiple pathways that protect cancer cells while simultaneously activating pathways that induce cancer cells' self-destruction.

In the paper, they concluded that "the results from our in-vitro and in-vivo studies reveal that COH-SR4 represents a novel candidate ... to target aggressive and drug-resistant lung cancers" and are working on further preclinical research in order to apply for human trials with the Food and Drug Administration, as well studying COH-SR4's ability to fight other cancers, diabetes and obesity.


Story Source:

The above story is based on materials provided by City of Hope. Note: Materials may be edited for content and length.


Cite This Page:

City of Hope. "Thwarting drug-resistant lung cancer with novel compound." ScienceDaily. ScienceDaily, 8 April 2014. <www.sciencedaily.com/releases/2014/04/140408154107.htm>.
City of Hope. (2014, April 8). Thwarting drug-resistant lung cancer with novel compound. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2014/04/140408154107.htm
City of Hope. "Thwarting drug-resistant lung cancer with novel compound." ScienceDaily. www.sciencedaily.com/releases/2014/04/140408154107.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins